查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984056

新一代体外诊断市场：按产品类型、技术、测试类型、检体类型、应用和最终用户分類的全球市场预测，2026-2032年

Next-Generation IVD Market by Product Type, Technology, Test Type, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计下一代体外诊断 (IVD) 市场在 2025 年的价值为 692.4 亿美元，在 2026 年增长至 730.9 亿美元，到 2032 年达到 1102 亿美元，复合年增长率为 6.86%。

主要市场统计数据
基准年 2025 692.4亿美元
预计年份：2026年 730.9亿美元
预测年份 2032 1102亿美元
复合年增长率 (%) 6.86%

透过从技术融合、监管演变和医疗保健服务体系变革的角度重新审视诊断策略转型的迫切需要，相关人员对成功的定义正在被重新定义。

当前体外诊断业界正处于快速技术创新、医疗服务模式变革以及对更快、更准确、资料整合型诊断日益增长的需求交汇的十字路口。临床相关人员需要的诊断解决方案不仅要提供准确的结果，还要能够无缝整合到临床流程中，支援分散式检查，并实现人群层面的监测。随着分子诊断技术的成熟、数位健康工具的普及以及照护现场检测（POC​​）的扩展，各组织需要重新思考其产品蓝图、伙伴关係和供应链策略，才能保持竞争力。

识别颠覆传统诊断模式的关键技术和营运变革，并为临床影响和商业性差异化开闢新途径。

在技​​术融合、新的临床需求以及对可操作数据的关注等因素的推动下，体外诊断领域正经历着多项变革性变化，从根本上改变其发展方向。首先，分子诊断正从专业检查室转向更常规的临床应用，聚合酵素链锁反应(PCR) 平台和等温扩增技术使得病原体和遗传标记的检测更加快速且灵敏。这种转变促使检测化学和试剂设计领域重新聚焦于在分散式环境中的稳健性。

本分析检视了美国近期关税措施如何重塑诊断设备和试剂整个生命週期的采购、定价结构和供应链韧性。

2025年美国关税的累积影响正对整个诊断价值链施加多方面的压力，促使企业重新评估采购、定价和在地化策略。关键仪器组件、试剂原料和成品的关税加剧了投入成本的波动，并增加了製造商和检查室采购作业的复杂性。为此，许多公司正在审查其供应商网络，以减少对受关税影响地区的依赖，并加快製造地的多元化。

我们进行详细的、多方面的細項分析，包括产品类型、技术、最终用户、应用、检体类型，以确定有针对性的商业化挑战和临床重点。

精细化的市场区隔方法揭示了每种产品类型、技术、最终用户、应用、检体类型的不同需求、部署模式和商业化路径。按产品类型划分，该市场包括化学分析仪、免疫检测和PCR仪等仪器，以及涵盖临床化学试剂、免疫检测和分子诊断剂的试剂和试剂盒，还有数据管理平台和维护服务等软体和服务。每种产品类型都需要不同的市场进入模式：仪器主要依靠资本财销售，试剂主要依靠持续消费和供应链优化，而软体和服务则主要依靠整合和生命週期收入。

本检验了美洲、欧洲、中东和非洲以及亚太地区的区域市场动态如何影响产品的采用、製造策略和市场进入管道。

区域趋势正在塑造美洲、欧洲、中东和非洲以及亚太地区的需求、创新中心和投资模式。在美洲，成熟的检查室网路和先进的报销机制持续推动对整合自动化、分子诊断平台和资料管理解决方案的需求，而大规模医院系统和参考实验室则在寻求可扩展的工作流程和检验的数位化整合。策略伙伴关係和在地化服务交付对于满足客户对快速部署、认证维护和持续试剂供应的期望变得日益重要。

了解製造商、软体供应商和服务供应商如何调整其产品组合、伙伴关係和供应链，以确保在诊断领域获得竞争优势。

产业领导者正积极整合平台、建立策略伙伴关係关係并采用以服务为中心的模式，以掌握不断成长的诊断机会。製造商正投资于模组化仪器架构，以支援多种检测项目，同时加快新检测产品的上市速度。此外，对试剂稳定性、标准化耗材介面和远距离诊断能力的配套投资，透过提高运作和降低总成本透明度，提升了客户维繫。

为产业领导者制定可操作的策略重点，以协调产品架构、资料整合、证据产生和弹性供应链，从而加速部署。

产业领导者应优先考虑整合产品开发、供应链韧性、证据产生和上市时间策略，以在下一代诊断时代取得成功。首先，他们应投资于模组化仪器设计和开放式耗材系统，以实现检测规模的快速扩展并减少对单一供应商的依赖。这有助于快速回应临床需求和关税相关的供应中断。这种架构的柔软性便于与各种软体生态系统集成，并支援涵盖集中式和分散式环境的混合部署模式。

为了确保可重复性和策略有效性，我们将解释构成此分析基础的高度透明、以访谈主导和多方面的证据检验调查方法。

本综合报告采用多面向、以资讯来源为导向的调查方法，主导为策略决策提供稳健透明的基础。主要资料来源包括对临床实验室主任、医院采购经理、诊断研发负责人和保险公司代表的结构化访谈，以获取关于技术要求、推广障碍和报销重点的第一手观点。这些定性见解与监管文件、同行评审文献、临床指南和行业公告等二级资讯来源进行检验，以检验技术和商业性趋势。

本文概述了技术整合、实证策略和供应链韧性将如何决定诊断领域未来的竞争优势。

体外诊断的未来正受到技术创新、医疗服务模式演变和政策趋势转变的共同影响而重塑。能够在这种环境下蓬勃发展的机构，将是那些整合模组化产品设计、建立稳健的数据策略和建立弹性供应链，同时投资于满足监管机构和医保报销相关人员需求的真实世界证据的机构。仪器、试剂和软体之间的相互作用不断创造捆绑式服务的机会，这些服务能够简化采购流程并提升临床效用。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 下一代体外诊断市场：依产品类型划分

  • 装置
    • 生化分析仪
    • 免疫检测装置
    • PCR设备
  • 试剂和试剂盒
    • 临床化学试剂
    • 免疫检测试剂
    • 分子诊断试剂
  • 软体服务
    • 资料管理软体
    • 维护服务

第九章 下一代体外诊断市场：依技术划分

  • 临床化学
    • 电化学
    • 光强度
  • 免疫检测
    • CLIA
    • ELISA
    • FIA
  • 微生物学
    • 培养方法
    • 分子
  • 分子诊断
    • 等温扩增
    • 基于PCR的
    • 定序碱基

第十章：按检测类型分類的下一代体外诊断市场

  • 定性
  • 定量
  • 半定量

第十一章检体类型分類的下一代体外诊断市场

  • 血
  • 唾液
  • 组织
  • 尿

第十二章 下一代体外诊断市场：依应用领域划分

  • 自体免疫疾病
    • 乳糜泻
    • 狼疮
    • 类风湿性关节炎
  • 循环系统
    • 心臟标记物
    • 脂质
  • 感染疾病
    • COVID-19
    • 肝炎
    • HIV
    • 结核
  • 神经病学
    • 阿兹海默症
    • 帕金森氏症
  • 肿瘤学
    • 血液疾病
    • 固体癌

第十三章 下一代体外诊断市场：依最终用户划分

  • 诊断检查室
    • 医院检查室
    • 测试承包组织
  • 医院和诊所
    • 二级医疗机构
    • 三级医疗中心
  • 护理点
  • 研究机构

第十四章 下一代体外诊断市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 下一代体外诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 下一代体外诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国下一代体外诊断市场

第十八章：中国的下一代体外诊断市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ABL SA Group
  • Agilent Technologies Inc.
  • Archer by Integrated DNA Technologies, Inc.
  • Becton, Dickinson and Company
  • Biomerieux SA
  • BioVendor-Laboratorni medicina AS
  • Cerba Research NV
  • Curetis NV
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fapon Biotech Inc.
  • Fulgent Genetics, Inc.
  • Geneseeq Technology Inc.
  • Genomic Labs Ltd.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • NGenBio Co., Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pillar Biosciences Inc.
  • QIAGEN GmbH
  • Sophia Genetics SA
  • Sysmex Europe SE
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Trivitron Healthcare
  • Vela Diagnostics Holding Pte Ltd.
Product Code: MRR-2E76C3E47F6A

The Next-Generation IVD Market was valued at USD 69.24 billion in 2025 and is projected to grow to USD 73.09 billion in 2026, with a CAGR of 6.86%, reaching USD 110.20 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 69.24 billion
Estimated Year [2026] USD 73.09 billion
Forecast Year [2032] USD 110.20 billion
CAGR (%) 6.86%

Framing the urgent transformation in diagnostic strategy as technological convergence, regulatory evolution, and care delivery shifts redefine success for industry stakeholders

The current moment for in vitro diagnostics is defined by a rapid intersection of technological innovation, shifting care delivery models, and increasing demands for diagnostic speed, precision, and data integration. Clinical stakeholders are seeking diagnostic solutions that not only return accurate results but also integrate seamlessly into care pathways, support decentralized testing, and enable population-level surveillance. As molecular methods mature, digital health tools gain traction, and point-of-care modalities proliferate, organizations must reassess product roadmaps, partnerships, and supply chain strategies to remain relevant.

Regulatory frameworks and payer expectations are concurrently evolving, emphasizing clinical utility, real-world evidence, and interoperability. These changes are prompting manufacturers to invest more heavily in validation studies, quality management, and post-market data collection. Moreover, providers and laboratories are reconfiguring service delivery to balance centralized high-throughput testing with near-patient diagnostics, requiring flexible instrumentation, consumables strategies, and maintenance models.

Against this backdrop, competitive differentiation is increasingly driven by the ability to combine robust analytical performance with streamlined workflow, adaptable software, and service offerings that reduce total cost of ownership. Companies that effectively translate emerging science into clinically meaningful, easy-to-deploy solutions will capture influence across diagnostic laboratories, hospitals and clinic networks, point-of-care environments, and research institutions. The introduction to this analysis frames the core forces at play and sets the stage for deeper discussion of transformative shifts, trade policy impacts, segmentation insights, and regional considerations.

Identifying the pivotal technological and operational shifts that are disrupting traditional diagnostic models and creating new avenues for clinical impact and commercial differentiation

Several transformative shifts are fundamentally changing the trajectory of in vitro diagnostics, driven by technological convergence, new clinical priorities, and an emphasis on actionable data. First, molecular diagnostics have moved from specialized laboratories toward more routine clinical use, with polymerase chain reaction platforms and isothermal amplification technologies enabling faster, sensitive detection of infectious agents and genetic markers. This shift is accompanied by a renaissance in assay chemistry and reagent design that prioritizes robustness across decentralized settings.

Second, digital integration and data management have become core differentiators. The ability to harmonize instrument outputs with laboratory information systems, cloud-based analytics, and decision-support tools enhances diagnostic value by enabling longitudinal patient tracking, population surveillance, and AI-assisted interpretation. Interoperability standards and cybersecurity considerations are now central design criteria for both software vendors and instrument manufacturers.

Third, the expansion of point-of-care testing reflects changing care delivery models that emphasize rapid diagnosis in outpatient clinics, emergency departments, and community settings. This trend is reshaping product engineering to focus on portability, simplified workflows, and low-maintenance operation. Concurrently, service models are evolving to include outcome-linked maintenance, remote diagnostics, and subscription-based reagent supply that align incentives across providers and vendors.

Finally, regulatory and reimbursement landscapes are adapting to accommodate innovative assays and digital diagnostics, driving manufacturers to generate not only analytical validation but also real-world clinical evidence. Together, these shifts demand an integrated commercial approach that balances innovation with pragmatic considerations around supply chains, manufacturing scalability, and post-market support.

Analyzing how recent United States tariff measures have reshaped sourcing, pricing structures, and supply chain resilience across the diagnostic instrument and reagent lifecycle

The cumulative impact of United States tariff actions in 2025 is exerting multidimensional pressure across the diagnostics value chain, prompting reassessment of sourcing, pricing, and localization strategies. Tariffs on key instrument components, reagent raw materials, and finished goods have amplified input cost volatility, intensifying procurement complexity for manufacturers and laboratories alike. In response, many firms are revisiting supplier networks to mitigate exposure to tariff-exposed geographies and are accelerating diversification of manufacturing footprints.

Beyond immediate cost implications, tariffs have affected capital equipment purchasing behavior. Healthcare organizations evaluating instrumentation purchases are factoring in extended total cost considerations, including potential import duties, logistical lead times, and maintenance parts availability. This has increased interest in domestically produced instruments or devices whose critical subcomponents originate in tariff-neutral jurisdictions, as well as in service contracts that include parts and reagent predictability to offset tariff-driven price fluctuations.

Strategically, tariffs have propelled a renewed focus on supply chain resilience and vertical integration. Companies are exploring onshoring of critical reagent production and localized assembly to stabilize delivery timelines and maintain competitive positioning. At the same time, regional regulatory and trade policy responses have introduced administrative complexity, with manufacturers required to manage differing compliance pathways and documentation to qualify for tariff exemptions or preferential treatment.

Taken together, the tariff environment in 2025 has shifted decision-making from short-term procurement arbitrage toward longer-term supply chain redesigns, supplier partnerships, and product strategies that emphasize modularity, local support, and predictable lifecycle economics.

Unpacking multidimensional segmentation across product, technology, end-user, application, test type, and sample type to reveal targeted commercialization imperatives and clinical priorities

A granular segmentation approach reveals differentiated requirements, adoption patterns, and commercialization pathways across product types, technologies, end users, applications, test types, and sample types. By product type, the landscape includes instruments-such as chemistry analyzers, immunoassay analyzers, and PCR instruments-alongside reagents and kits that span clinical chemistry reagents, immunoassay reagents, and molecular diagnostics reagents, and finally software and services comprised of data management platforms and maintenance services. Each product class demands distinct go-to-market models: instruments require capital sales, reagents depend on recurring consumption and supply chain optimization, and software and services center on integration and lifecycle revenue.

Technology segmentation highlights the diversity of underlying modalities, including clinical chemistry platforms that rely on electrochemical or photometric detection, immunoassay systems utilizing CLIA, ELISA, or FIA formats, microbiology approaches that range from culture-based methods to molecular assays, and molecular diagnostic techniques that include isothermal amplification, PCR-based workflows, and sequencing-based solutions. Technology choices influence assay turnaround time, sensitivity, infrastructure requirements, and laboratory staffing models, which in turn shape adoption across different clinical settings.

End-user segmentation spans diagnostic laboratories-both hospital laboratories and reference laboratories-hospitals and clinics that include secondary care hospitals and tertiary care centers, point-of-care locations, and research institutes. Adoption dynamics vary by end user, with high-throughput labs prioritizing automation and throughput, hospitals emphasizing integrated workflows and point-of-care responsiveness, and research institutes focusing on flexibility and novel assay adoption. Application-level differentiation includes autoimmune disease testing across celiac, lupus, and rheumatoid arthritis; cardiology assays such as cardiac markers and lipid panels; infectious disease testing for COVID-19, hepatitis, HIV, and tuberculosis; neurology diagnostics for Alzheimer's and Parkinson's disease; and oncology covering hematological and solid tumor testing, each with unique clinical evidence and regulatory pathways.

Test type distinctions-qualitative, quantitative, and semi-quantitative-combined with sample type considerations like blood, saliva, tissue, and urine, further influence assay design, regulatory classification, and user training requirements. This multifaceted segmentation underscores the necessity for tailored commercial strategies that align product development, regulatory planning, reimbursement engagement, and customer support with the specific demands of each segment.

Examining how regional market dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific are influencing adoption, manufacturing strategies, and market access paths

Regional dynamics are shaping demand, innovation hubs, and investment patterns in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established laboratory networks and advanced reimbursement frameworks continue to drive demand for integrated automation, molecular platforms, and data management solutions, while large hospital systems and reference laboratories push for scalable workflows and validated digital integrations. Strategic partnerships and localized service offerings are increasingly important to meet customer expectations for rapid installation, certified maintenance, and reagent continuity.

In the Europe, Middle East & Africa region, heterogeneous regulatory requirements and diverse healthcare financing models create both complexity and opportunity. The region's fragmented market structure rewards manufacturers who can navigate varied conformity assessment pathways, demonstrate clinical utility across multiple health systems, and offer flexible commercial models. Moreover, investment in public health infrastructure and infectious disease surveillance is prompting demand for both decentralized testing and robust laboratory reference capabilities.

Asia-Pacific presents a mosaic of mature and emerging markets where rapid adoption of molecular diagnostics, strong interest in point-of-care modalities, and substantial local manufacturing capacity are driving competitive intensity. Regional supply chain ecosystems, including component suppliers and reagent manufacturers, are enabling faster product localization, while differing clinical practice patterns and regulatory priorities require tailored evidence generation and market access approaches. Across all regions, sustainability considerations, workforce availability, and digital infrastructure will continue to influence deployment timelines and customer expectations.

Identifying how manufacturers, software vendors, and service providers are aligning portfolios, partnerships, and supply chains to secure competitive advantage in diagnostics

Leading industry players are pursuing a mix of platform consolidation, strategic partnerships, and service-centric models to capture expanding diagnostic opportunities. Manufacturers are investing in modular instrument architectures that support a broad assay menu while reducing time to market for new tests. Complementary investments in reagent stability, standardized consumable interfaces, and remote diagnostics capabilities are enhancing customer retention through improved uptime and total cost clarity.

Software and data management providers are emerging as pivotal collaborators, offering interoperability layers, cloud analytics, and decision-support tools that increase the clinical utility of laboratory outputs. These vendors are also engaging in co-development arrangements with instrument manufacturers to deliver turnkey solutions that simplify procurement and integration for healthcare providers. At the same time, service organizations are expanding maintenance, training, and reagent lifecycle programs to align commercial incentives with laboratory performance metrics.

Competitive differentiation is further influenced by strategic M&A activity and alliance formation aimed at closing gaps in assay portfolios, geographic presence, and digital capabilities. Companies that can demonstrate credible evidence packages, efficient regulatory pathways, and robust post-market surveillance are better positioned to secure long-term contracts with health systems and large reference laboratories. Supply chain excellence-including diversified sourcing, localized manufacturing, and responsive logistics-remains a critical determinant of commercial resilience and customer trust.

Actionable strategic priorities for industry leaders to align product architecture, data integration, evidence generation, and resilient supply chains to accelerate adoption

Industry leaders should prioritize an integrated approach that aligns product development, supply chain resilience, evidence generation, and go-to-market strategies to succeed in the next-generation diagnostics era. First, invest in modular instrument designs and open consumable systems that allow rapid assay expansion and reduce dependence on single-source components, thereby enabling faster response to clinical needs and tariff-related supply disruptions. This architectural flexibility will also facilitate integration with diverse software ecosystems and support hybrid deployment models across centralized and decentralized settings.

Second, strengthen data strategies by embedding interoperable data management capabilities into core offerings. This involves adopting industry data standards, ensuring robust cybersecurity, and developing analytics that translate laboratory outputs into actionable clinical insights. Demonstrating how data integration improves clinical pathways and operational efficiency will be essential for payer and provider adoption.

Third, develop evidence generation roadmaps that extend beyond analytical validation to include real-world performance, health economic assessments, and outcomes studies that support reimbursement and clinical guideline inclusion. Collaborate with key opinion leaders, clinical networks, and reference laboratories to generate reproducible multi-center data that aligns with regulatory and payer expectations.

Finally, proactively redesign supply chain and commercial models to mitigate tariff exposure, including nearshoring critical manufacturing, diversifying suppliers, and offering flexible commercial terms such as reagent-as-a-service or bundled maintenance agreements. Prioritize customer-centric service frameworks that emphasize uptime, training, and local technical support to build durable customer relationships and unlock long-term adoption.

Describing the transparent, interview-led, and evidence-triangulated research methodology underpinning the analysis to ensure reproducibility and strategic relevance

This research synthesis integrates a multi-source, evidence-based methodology designed to provide a robust and transparent foundation for strategic decision-making. Primary inputs include structured interviews with clinical laboratory directors, hospital procurement leaders, diagnostic R&D heads, and payers to capture first-hand perspectives on technology requirements, adoption barriers, and reimbursement priorities. These qualitative insights are triangulated with secondary sources such as regulatory filings, peer-reviewed literature, clinical guidelines, and industry announcements to validate technological trends and commercial movements.

Analytical approaches employ cross-segmentation mapping to assess how product types, technologies, end users, applications, test types, and sample matrices interact to influence adoption pathways and commercialization tactics. The methodology prioritizes reproducibility by documenting data provenance, interview protocols, and analytic assumptions, while sensitivity analyses are applied to scenario testing related to supply chain disruptions and policy changes.

Ethical considerations and data governance are integral to the research approach, ensuring that patient-level data used in secondary analysis are de-identified and that proprietary information obtained through interviews is anonymized unless explicit permission for attribution was provided. The resulting synthesis aims to deliver actionable insights that are defensible, transparent, and aligned with stakeholder realities across clinical, regulatory, and commercial domains.

Concluding synthesis on how technological integration, evidence strategies, and supply chain resilience will determine future competitive advantage in diagnostics

The trajectory of in vitro diagnostics is being reshaped by a convergence of technological innovation, evolving care delivery models, and shifting policy dynamics. Organizations that successfully navigate this landscape will be those that integrate modular product design, robust data strategies, and resilient supply chains while investing in the real-world evidence necessary to satisfy regulatory and reimbursement stakeholders. The interplay of instrumentation, reagents, and software continues to create opportunities for bundled offerings that simplify procurement and enhance clinical utility.

Regional differentiation and tariff-related supply chain considerations add layers of commercial complexity, but they also create openings for manufacturers that can localize production, offer service-centric commercial models, and demonstrate clear clinical and economic value. End users across diagnostic laboratories, hospitals and clinics, point-of-care settings, and research institutes will seek partners who can deliver predictable performance, seamless integration, and accountable service models.

In conclusion, the next wave of competitive advantage in diagnostics will be earned by organizations that translate technical capability into deployable solutions aligned with clinical workflows, payer requirements, and operational realities. Strategic investments in modular platforms, interoperable software, localized manufacturing, and evidence generation will position stakeholders to meet emerging clinical demands and capture sustained relevance in the diagnostic ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next-Generation IVD Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Chemistry Analyzers
    • 8.1.2. Immunoassay Analyzers
    • 8.1.3. PCR Instruments
  • 8.2. Reagents & Kits
    • 8.2.1. Clinical Chemistry Reagents
    • 8.2.2. Immunoassay Reagents
    • 8.2.3. Molecular Diagnostics Reagents
  • 8.3. Software & Services
    • 8.3.1. Data Management Software
    • 8.3.2. Maintenance Services

9. Next-Generation IVD Market, by Technology

  • 9.1. Clinical Chemistry
    • 9.1.1. Electrochemical
    • 9.1.2. Photometric
  • 9.2. Immunoassay
    • 9.2.1. Clia
    • 9.2.2. Elisa
    • 9.2.3. Fia
  • 9.3. Microbiology
    • 9.3.1. Culture Based
    • 9.3.2. Molecular
  • 9.4. Molecular Diagnostic
    • 9.4.1. Isothermal Amplification
    • 9.4.2. PCR Based
    • 9.4.3. Sequencing Based

10. Next-Generation IVD Market, by Test Type

  • 10.1. Qualitative
  • 10.2. Quantitative
  • 10.3. Semi Quantitative

11. Next-Generation IVD Market, by Sample Type

  • 11.1. Blood
  • 11.2. Saliva
  • 11.3. Tissue
  • 11.4. Urine

12. Next-Generation IVD Market, by Application

  • 12.1. Autoimmune Diseases
    • 12.1.1. Celiac
    • 12.1.2. Lupus
    • 12.1.3. Rheumatoid Arthritis
  • 12.2. Cardiology
    • 12.2.1. Cardiac Markers
    • 12.2.2. Lipids
  • 12.3. Infectious Diseases
    • 12.3.1. Covid-19
    • 12.3.2. Hepatitis
    • 12.3.3. Hiv
    • 12.3.4. Tuberculosis
  • 12.4. Neurology
    • 12.4.1. Alzheimer's Disease
    • 12.4.2. Parkinson's Disease
  • 12.5. Oncology
    • 12.5.1. Hematological
    • 12.5.2. Solid Tumor

13. Next-Generation IVD Market, by End User

  • 13.1. Diagnostic Laboratories
    • 13.1.1. Hospital Laboratories
    • 13.1.2. Reference Laboratories
  • 13.2. Hospitals & Clinics
    • 13.2.1. Secondary Care Hospitals
    • 13.2.2. Tertiary Care Centers
  • 13.3. Point Of Care
  • 13.4. Research Institutes

14. Next-Generation IVD Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Next-Generation IVD Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Next-Generation IVD Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Next-Generation IVD Market

18. China Next-Generation IVD Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. ABL SA Group
  • 19.6. Agilent Technologies Inc.
  • 19.7. Archer by Integrated DNA Technologies, Inc.
  • 19.8. Becton, Dickinson and Company
  • 19.9. Biomerieux SA
  • 19.10. BioVendor - Laboratorni medicina A.S.
  • 19.11. Cerba Research NV
  • 19.12. Curetis N.V.
  • 19.13. Danaher Corporation
  • 19.14. F. Hoffmann-La Roche Ltd.
  • 19.15. Fapon Biotech Inc.
  • 19.16. Fulgent Genetics, Inc.
  • 19.17. Geneseeq Technology Inc.
  • 19.18. Genomic Labs Ltd.
  • 19.19. Illumina, Inc.
  • 19.20. Invivoscribe, Inc.
  • 19.21. NGenBio Co., Ltd.
  • 19.22. Otsuka Pharmaceutical Co., Ltd.
  • 19.23. Pillar Biosciences Inc.
  • 19.24. QIAGEN GmbH
  • 19.25. Sophia Genetics SA
  • 19.26. Sysmex Europe SE
  • 19.27. Tempus Labs, Inc.
  • 19.28. Thermo Fisher Scientific Inc.
  • 19.29. Trivitron Healthcare
  • 19.30. Vela Diagnostics Holding Pte Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION IVD MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT-GENERATION IVD MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEXT-GENERATION IVD MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES NEXT-GENERATION IVD MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA NEXT-GENERATION IVD MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEXT-GENERATION IVD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CHEMISTRY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CHEMISTRY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CHEMISTRY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTICS REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTICS REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTICS REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MAINTENANCE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MAINTENANCE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELECTROCHEMICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELECTROCHEMICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELECTROCHEMICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PHOTOMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PHOTOMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PHOTOMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY FIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY FIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY FIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CULTURE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CULTURE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEQUENCING BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEQUENCING BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEQUENCING BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY QUALITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY QUALITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEMI QUANTITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEMI QUANTITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEMI QUANTITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CELIAC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CELIAC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CELIAC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LUPUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LUPUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LUPUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIAC MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIAC MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LIPIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LIPIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LIPIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COVID-19, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COVID-19, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COVID-19, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TUBERCULOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TUBERCULOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TERTIARY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TERTIARY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TERTIARY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 302. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 306. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 310. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 312. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 316. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 318. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 320. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY DIAGNO